HUPO 2025
bioinformatics hub SESSIONS WITH INTERACTIVE PRESENTATIONS
Important dates
June 20, 2025
Proposal Submission Deadline
July 20, 2025
Notification of Acceptance/Decline
August 29, 2025
Final Program Due for Onsite Materials
November 9 – 13, 2025
Congress
All proposals must be submitted online by clicking the link below:
Call for Bioinformatics Hub Sessions with Interactive Presentations
The HUPO 2025 Conference Organizing Committee invites submissions from individuals or groups to conduct interactive presentations at the Bioinformatics Hub, which will hold sessions during HUPO 2025 (November 10, 11 and 12). Sessions are either 1 or 1.5 hours in length.
We welcome proposals for Bioinformatics Hub Sessions that provide engaging and interactive forums for discussion. Sessions should include discussions and opportunities to form collaborations and be led by at least two co-organizers who will host the session on site. Panel discussions and small group problem solving are examples of good ways to engage attendees. A typical Bioinformatics Hub Session will discuss subjects, such as open challenges in the field, areas where more computational efforts are needed or emerging and growing initiatives that require community input. Proposals should not be featuring standard scientific talks including only a few questions. Interactive participation is key! Any topics related to bioinformatics of proteomics are welcome.
Submissions are NOW CLOSED and all submitted proposals are being reviewed.
What to Include
Submissions should also include the following information:
- Title of the Bioinformatics Hub Session
- Short summary (200 words or less) of the session and the interactivities planned
- One sentence description for onsite materials
- Name and email of the contact people who will lead the Session and be responsible for Session correspondence
- Name of other Bioinformatics Hub Session participants with institutional affiliations and email addresses
- Length of the proposed session (1 or 1.5 hours)
Important Information
Important things to note before submitting a proposal:
- If your Bioinformatics Hub Session is accepted, it will be included in the schedule for the Bioinformatics Hub track and scheduled to take place in the dedicated room for the Bioinformatics Hub.
- The Session will be listed in the program on the website, mobile app and in all official Congress materials as part of the Bioinformatics Hub schedule. You are encouraged to personally invite people to attend the Session. Anyone attending the Session will have to be registered for the HUPO 2025 Congress.
- It will be the organizer’s responsibility to make all arrangements for the Session, including speaker/participants arrangements.
- The final agenda for inclusion in the onsite materials must be submitted to the Congress Secretariat no later than August 29, 2025.
Review Process
Workshops will be reviewed by an international expert reviewer panel and selected based on:
- Quality of proposed interactive and engaging activities
- Interest in the Bioinformatics topic
- Diversity of co-organizers and speakers in alignment with HUPO’s Mission (e.g., people from different regions and gender representation)
- Alignment with HUPO Initiatives (https://hupo.org/Initiatives)
Applications of Proteomics in Biopharma and Food Industry
- Antibodies, Drugs, Biotherapeutics
- Bioprocessing, Molecular Pharming, Biopharma
- Diagnostics
- Future Food (E.G., Cultured Food)
- Quality Control, Counterfeit Detection, Food Fraud
Artificial Intelligence in Proteomics
- AI in Mass Spectrometry, Biological Insights, Classification, Data Analysis
- Machine Learning, Deep Learning, Supervised, Learning, Unsupervised Learning, Reinforcement Learning, Artificial Intelligence
Cell Signaling and Proteome Dynamics
- Protein Homeostasis, Stability, Turnover
- PTM Dynamics Signal
- Transduction
Chemoproteomics and Drug Discovery
- Activity and Thermal Profiling, Energetics-Based Protein Separation
- Biopharma
- Chemoproteomics for PTM Profiling
- Click Chemistry, Chemo-Enzymatic
- Machine-Learning and Computational Modeling
- Small Molecule Modulators, Molecular Glue, Protein Degraders
Clinical Proteomics
- AI And Computational Approaches in The Clinic
- Biomarkers, Diagnostics, Prognostics
- Clinical Cohorts, Clinical Trials, Population Health and Studies
- Precision and Personalized Medicine
- Targeted Therapies, Therapeutics
- Tissue Biopsies, Body Fluids
Data Integration and Innovative Computational Methods for System Biology
- Functional Enrichment, Differential Abundance, New Statistical Analyses
- Integrative Bioinformatics
- Network Biology
- Novel Software, Computational Methodology, Databases and Repositories, Annotations
- Proteogenomics
Environmental and Human Microbiomes
- Bacteria, Fungi, Parasites, Viruses, Phages, Etc.
- Metaproteomics, Meta-Metabolomics
- Microbiota
- Source (E.G., Marine, Soil, Gut, Skin, Saliva, Microorganisms)
Glycoproteomics and Post-translational Modifications
- Chemical Modifications
- Glycobiology
- Glycosylation, Phosphorylation, Acetylation, Ubiquitination, Methylation, etc.
- N-terminomics, Degradomics
Host-Pathogen, Infectious Diseases and Virology
- Antimicrobial Resistance
- Bacteria, Fungi, Parasites, Viruses, Phages, etc.
- Immunobiology
- Pandemic Preparedness
Immunopeptidomics and Immunoproteomics
- Antigen Presentation, Antibodies
- Autoimmunity
- HLA/MHC Class I & Class II
- Immunopeptides, Immunoproteins
- Method and Technology Development
- Vaccination, Immunogenicity, Immune Response
Innovations in Proteomics Methodology
- Analytical Techniques
- Computational Analysis
- High-Throughput, Deep Proteomics
- Method, Technology, and Instrumentation Development
- Sample Preparation
- Workflow Automation/Integration
Multi-Omics and Systems Biology
- Genomics, Transcriptomics, Metabolomics, Lipidomics, Integrative Omics
- Multi-Omics Data Integration
- Network Biology and Modeling
New Technologies for Large Scale Proteomics
TBC
Non-Canonical Translation and Microproteins
- Non-Canonical Open-Reading Frames and Proteins
- Novel and Alternative Proteins
- Small Open Reading Frames and Proteins
Novel Computational Analysis of Mass Spectrometry Data
- Computational Methods for Data Acquisition
- Data Processing (E.G., De-Noising, Normalization)
- De Novo Sequencing
- Novel Search Engines, Strategies, Peptide and Proteins Identification, Open Modification Searches
- Quantification
One Health One World
- Animal, Human, Environmental Health
- Plant and Agricultural Proteomics
- Sustainability
- Veterinary-Based Proteomics
Proteome Organization
- Organelles, Membranes, Extracellular Vesicles, etc.
- Protein Complexes
- Protein-protein Interactions, Proximal Proteomics, Cross-linking
- Secretomics
- Surface Proteome
Proteome in Human Diseases
- Aging
- Cancer
- Cardiovascular
- Gastrointestinal Diseases
- Metabolic Diseases and Diabetes
- Neuroscience, Neurodegenerative Disorders, Psychiatric Disorders
Quantitative Proteomics
- Chemical and Metabolic Labeling
- Data Independent Analysis and Data Dependent Analysis
Label-free Quantification - Quantitative Approach
Single Cell Proteomics
- Low Copy Number
- Mass Cytometry and Imaging
- Method And Technology Development
- Single Cell Multi-Omics
- Single Organelle, Single Cell-Type
Spatial and Imaging Proteomics
- Imaging Processing and Analysis
- Mass Spectrometry Imaging
- Microscopy
- Proximity Labelling, Cross-Linking
- Tissue and Cell imaging
Structural Proteomics
- Chemical Footprinting
- Cryo-EM
- HDX, Cross-linking, Limited Proteolysis
- Machine-learning and Computational Modeling
- Native Mass Spectrometry
- Thermal Profiling and Energetics-based Protein Separation, Protein Folding
Technological Advancements
TBC
Top-Down Proteomics and Proteoforms
- Combinatorial Modifications
- Middle-down
- Native Mass Spectrometry
- Protein Complexes
Frequently Asked Questions
Abstract titles will be released July 23, 2024.
The full abstract bodies will be released on August 14, 2024 at 10:00 PDT, except those abstracts included in the WCLC 2024 Press Program.
Abstracts selected for inclusion in the WCLC press program, including Presidential Sessions abstracts, will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first.
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations during the abstract submission process.
The submission of single case reports is not permitted, however, submission of case series with a minimum of 3 cases but preferably 5, including literature review is accepted.
July 12, 2024 is the withdrawal deadline for regular abstracts and August 9 for LBA abstracts.
The presenting author registration deadline (except LBA abstracts) is July 12, 2024 (23:59 PDT). Abstract presentations for a presenter (except LBA abstracts) not registered by this date will be withdrawn from the program.
- LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines. Examples include randomized phase II and/or III trials, and large single arm phase II trials in rare subtypes of thoracic malignancies. LBA’s in other disciplines that change clinical practice within the year will also be considered.
- LBA designation is not a means for extending the regular abstract deadline. Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
- For abstracts that do not meet LBA requirements the authors will be given 48 hours to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.
Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. However, Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present poster or e-poster presentations.
Associated manuscripts for any abstract selected for presentation at WCLC can be submitted to a peer reviewed journal prior to presentation at WCLC but must not be published prior to the presentation at WCLC. Simultaneous publications are encouraged.
All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Series abstracts must be fully completed by the April 5, 2024 deadline.
Any Regular Abstracts and Case Series that are incomplete after the April 5, 2024 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the April 5, 2024 deadline without Results and Conclusions as those sections are optional for CTPS submissions.
To submit a late breaking abstract, you must submit a placeholder abstract including all components of the abstract except for the Results and Conclusions by the April 5, 2024 deadline.
Authors can only be listed as the Presenting Author on two (2) abstracts but can be co-author on any number of abstracts.
There is no charge to submit an abstract to WCLC.
The authors of the abstract, however, IASLC reserves the right to sell and retain any revenue/income from selling the abstracts, presentation materials or recordings of the presentations. Please refer to the detailed terms and conditions that authors have to agree to during the abstract submission.
Copyright is with the authors, however, IASLC reserves the right to publish and sell copies/recordings of the presentation materials.
The clinical trials must be registered in clinicaltrials.gov or an applicable one from their country/regulatory body.
No. You need to attend WCLC 2024 in person to present your abstract.
No, it’s not required.
The video platform will be available for 3 months after WCLC.
